29/03/2021at 12:50

Trial with Danish coronavirus therapy is prioritized in the UK

Union Therapeutics' trial with the drug niclosamide for treating Covid-19 patents with kidney diseases has gained further support from UK authorities.

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The National Institute for Health Research (NIHR) in the UK has given special status to a study from Danish biotech company Union Therapeutics, according to a press release from the company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Union Therapeutics expands Covid-19 program with nasal spray
For subscribers
EU vaccine rules may disrupt global supply, including to allies
For subscribers
Trust in Astrazeneca vaccine is dropping in Europe
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Hearing health

William Demant Invest report reveals GN Group stake

The investment firm’s ownership share in GN Group was enough to foil plans to raise DKK 7bn.

For subscribers

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers